Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22;Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36;Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 1;Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 22;Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 36;Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs);Number of Participants Reporting Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs);Number of Participants With Laboratory Test Results Based on US Food and Drug Administration (FDA) Toxicity Grading Guidance;Number of Participants With Solicited Injection Site Reactions;Number of Participants With Solicited Systemic Reactions;Number of Participants With Unsolicited Adverse Events;Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22;Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36;Percentage of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36;Percentage of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22

Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22;Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36;Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 1;Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 22;Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine at Day 36;Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs);Number of Participants Reporting Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESIs) and Medically Attended Adverse Events (MAAEs);Number of Participants With Laboratory Test Results Based on US Food and Drug Administration (FDA) Toxicity Grading Guidance;Number of Participants With Solicited Injection Site Reactions;Number of Participants With Solicited Systemic Reactions;Number of Participants With Unsolicited Adverse Events;Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22;Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36;Percentage of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36;Percentage of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22

2-fold and 4-fold rise in neutralizing antibody titer;Fold-rise in neutralizing antibody titer;Neutralizing antibody titer;Occurrence of neutralizing antibody seroconversion;Presence of immediate adverse events;Presence of medically attended adverse events;Presence of out-of-range biological test results;Presence of serious adverse events (SAE) and adverse events of special interest (AESI);Presence of solicited injection site reactions and systemic reactions;Presence of unsolicited adverse events

2-fold and 4-fold rise in neutralizing antibody titer;Fold-rise in neutralizing antibody titer;Neutralizing antibody titer;Occurrence of neutralizing antibody seroconversion;Presence of immediate adverse events;Presence of medically attended adverse events;Presence of out-of-range biological test results;Presence of serious adverse events (SAE) and adverse events of special interest (AESI);Presence of solicited injection site reactions and systemic reactions;Presence of unsolicited adverse events